Exclusive Summary

• - Patents are largely expired worldwide with generics present in multiple regions, enabling rapid distribution entry.
• - A large and growing patient base (≈76M in 2020, ≈95M by 2030) requires lifelong therapy, ensuring steady demand.
• - As a first-line PGA, tafluprost reduces IOP by ~25–33%; preservative-free/low-irritation formulations suit dry-eye and BAK-intolerant patients.
• - Competition is moderate due to higher sterile-packaging barriers; robust PF packaging and complete CTD dossier create differentiation and faster registrations.
• - A ~30–60% price advantage vs originator supports reimbursement access and tender competitiveness.